scholarly journals Herbs’ Disease-matched Pharmacological Mechanisms of HuanglianJiedu Decoction in Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease

2022 ◽  
Author(s):  
Su-Ya Ma ◽  
Xu Wang ◽  
Jing Shi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Signaling Pathway ◽  
Psychological Symptoms ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Network Pharmacology ◽  
Scutellariae Radix ◽  
Coptidis Rhizoma ◽  
Behavioral And Psychological Symptoms

Abstract Along with cognitive deficit, behavioral and psychological symptoms in dementia (BPSD) is another characteration of Alzheimer's disease that hamper clinical management and exacerbate burden for caregivers. However, therapeutic management of BPSD remains challenging. HuanglianJiedu decoction (HLJDD), a traditional Chinese prescription which contains Coptidis rhizome(Huang lian), Scutellariae radix (Huang-qin), Phellodendri chinrnsis cortex (Huang-bai) and Gardeniae fructus (Zhi-zi), is applied to treat BPSD. So elucidating the herbs’ disease-matched pharmacological mechanisms underlying HLJDD, further put forward each herbs’ disease-matched combination are critical to the application of HLJDD. In this study, network pharmacology was used to determine the targets and biological processes regulated by HLJDD in the treatment of BPSD. Moreover, molecular docking was utilized to evaluate the binding activity between the herbs' main active ingredients and neurotransmitter receptors. The results showed that the KEGG signaling pathway of HLJDD in treating BPSD mainly lies in TNF signaling pathway and AGE-RAGE signaling pathway in diabetic complications. Scutellariae radix and Phellodendri chinrnsis cortex exhibited better anti-BPSD effects when compared to Coptidis rhizoma and Gardeniae fructus. Scutellariae radix exhibited superior anti-neuroinflammation functions, with better blood vessel regulation effects. Phellodendri chinrnsis cortex showed a higher binding affinity to the dopamine D2 receptor (DRD2) and 5-hydroxytryptamine receptor 2A (HTR2A). Coptidis rhizoma and Gardeniae fructus were better in neuronal signaling. In conclusion, for treating BPSD, Scutellariae radix and Phellodendri chinrnsis cortex are the principal herbs while Coptidis rhizoma and Gardeniae fructus are the ancillary herbs. Beta-sitosterol, stigmasterol, chelerythrine, campesterol and berberine are the potential effective ingredients in treating BPSD.

scholarly journals Novel Combination of HuanglianJiedu Decoction in Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease

2021 ◽  
Author(s):  
Su-Ya Ma ◽  
Xu Wang ◽  
Jing Shi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychological Symptoms ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Binding Activity ◽  
Network Pharmacology ◽  
Scutellariae Radix ◽  
Coptidis Rhizoma ◽  
Behavioral And Psychological Symptoms

Abstract Alzheimer's disease (AD) is characterized by progressive cognitive decline. Besides cognitive deficit, AD is also characterized by behavioral and psychological symptoms in dementia (BPSD). However, therapeutic management of BPSD remains challenging. HuanglianJiedu decoction (HLJDD), a traditional Chinese prescription, consisting of four herbs, is applied to treat AD, especially AD with BPSD. Though HLJDD, has the traditional combination with the principal herb Coptidis rhizoma (Huang-lian), it might, however, not be suitable for treating BPSD. Elucidating the mechanism underlying each herb is critical to the disease-matched combination of HLJDD. In this study, network pharmacology was used to determine the targets and biological processes regulated by HLJDD in the treatment of BPSD. Moreover, molecular docking was utilized to evaluate the binding activity between the herbs' main active ingredients and neurotransmitter receptors. The results showed that Scutellariae radix (Huang-qin) and Phellodendri chinrnsis cortex (Huang-bai) exhibited better anti-BPSD effects when compared to Coptidis rhizoma and Gardeniae fructus (Zhi-zi). Scutellariae radix exhibited superior anti-neuroinflammation functions, with better blood vessel regulation effects. Phellodendri chinrnsis cortex showed a higher binding affinity to the dopamine D2 receptor (DRD2) and 5-hydroxytryptamine receptor 2A (HTR2A). Coptidis rhizoma and Gardeniae fructus were better in neuronal signaling. In conclusion, for treating BPSD, Scutellariae radix and Phellodendri chinrnsis cortex are the principal herbs while Coptidis rhizoma and Gardeniae fructus are the ancillary herbs.

scholarly journals Novel Compatibility of Huanglianjiedu Decoction in Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease1

2020 ◽  
Author(s):  
Su-Ya Ma ◽  
Xu Wang ◽  
Xiang-Yi Du ◽  
Ming-Wan Su ◽  
Xuan Yao ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychological Symptoms ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Binding Activity ◽  
Network Pharmacology ◽  
Scutellariae Radix ◽  
Behavioral And Psychological Symptoms

Abstract Background: Alzheimer's disease (AD) is characterized by progressive cognitive decline. Behavioral and psychological symptoms in dementia (BPSD) are another critical characterization of AD besides cognitive deficit. However, the pharmacological treatment of BPSD remains challenging. HuanglianJiedu decoction (HLJDD), which consists of four herbs, is applied to treat Alzheimer's disease in traditional Chinese medicine, especially AD with BPSD. While the frequently used compatibility of HLJDD, whose principal ingredient is Coptidis Rhizoma (Huang-lian, CR), may not be suitable for treating BPSD. Elucidating the mechanism underlying each herb is critical to HLJDD's pertinent compatibility.Methods: We utilized network pharmacology to analyze the herbs' targets and biological processes for treating BPSD in HLJDD and employed molecular docking to explore the binding activity between herbs' main active ingredients and neurotransmitter receptors. Results: Results showed that Scutellariae Radix (Huang-qin, SR) and Phellodendri Chinrnsis Cortex (Huang-bai, PCC) have better anti-BPSD effects than CR and Gardeniae Fructus (Zhi-zi, GF). SR has a better anti-neuroinflammation function, can better regulate blood vessels. PCC has a higher binding affinity with Dopamine D2 receptor (DRD2) and 5-hydroxytryptamine receptor 2A (HTR2A). CR and GF may be better for neuronal signaling.Conclusion: For treating BPSD, SR and PCC are the principal ingredients while CR and GF are the ancillary herbs.

scholarly journals Shen-Zhi-Ling Oral Liquid Improves Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Weidong Pan ◽  
Qiudong Wang ◽  
Shin Kwak ◽  
Yu Song ◽  
Baofeng Qin ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Rating Scale ◽  
Psychological Symptoms ◽  
Fluctuation Analysis ◽  
Double Blind ◽  
Oral Liquid ◽  
Detrended Fluctuation ◽  
Behavioral And Psychological Symptoms

We evaluated the effects of the traditional Chinese medicine (TCM) Shen-Zhi-Ling oral liquid (SZL) on the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease (AD). Among 98 patients with AD and BPSD enrolled (mean age, 57.2 ± 8.9 years old), 91 (M = 55,F = 36; mean age, 57.2 ± 9.7 years old) completed the study. Patients took either SZL (n=45) or placebo granules (n=46) in a double-blind manner for 20 weeks while maintaining other anticognitive medications unchanged. Changes in BPSD between week 0, week 10, week 20, and week 25 were assessed using the behavioral pathology in Alzheimer’s disease (BEHAVE-AD) rating scale and the neuropsychiatric inventory (NPI), detrended fluctuation analysis (DFA) represented by diurnal activity (DA), evening activity (EA), and nocturnal activity (NA) according to actigraphic recordings. SZL but not placebo oral liquid delayed the development of BPSD significantly according to the changes in some of the clinical scores and the EA and NA parameters of DFA at week 20 compared with week 0. No side effects were observed in laboratory tests. The results indicate that SZL might delay the development of BPSD in AD patients and thus is a potentially suitable drug for long-term use.

Sign in / Sign up

Export Citation Format

Share Document